Lumen and Novo Nordisk link up on oral biologics for cardiometabolic disease

In a second cardiometabolic deal signed this month, Danish diabetes care giant Novo Nordisk (NOV: N) has now entered into a collaboration with privately-held US biotech Lumen Bioscience.